Is Avonib covered by medical insurance? Analysis of the latest reimbursement policy and patients’ self-pay situation in 2025

Ivosidenib (Ivosidenib) has been launched in China, but has not yet been included in the scope of medical insurance reimbursement. This means that patients are responsible for the full cost of using the drug. According to the drug pricing situation, the market price of ivonib is approximately RMB 30,000 to RMB 40,000. The specific price may vary depending on the region, hospital and pharmacy. Therefore, patients are advised to consult their local hospital pharmacy to obtain accurate price information when purchasing.

Since it has not yet been included in medical insurance, the cost of ivonib may be a large financial burden for patients, especially for patients who need to use the drug for a long time. The cost issue may affect the continuity of treatment. Many patients may face high out-of-pocket expenses, which may constitute a barrier to treatment for patients with modest financial means.

In contrast, there are already generic drugs of ivonib on the overseas market, such as Laotian generic drugs, which are cheaper than domestic original drugs, about more than 3,000 yuan. The ingredients of these generic drugs are basically the same as the original drugs and can provide the same therapeutic effect, so they have become the choice of some patients. However, patients need to be aware that generic drugs may have some differences in quality control, drug purchase channels, etc. It is recommended to make a choice under the guidance of a doctor.

Generally speaking, the fact that ivonib has not been included in medical insurance makes its use more expensive, which is a considerable financial burden for many patients who need treatment. As the medical insurance policy gradually improves, more drugs may enter the scope of medical insurance in the future. It is hoped that ivonib can be included as soon as possible, thereby reducing the financial burden on patients and improving treatment accessibility. During this period, patients should choose appropriate drug purchase channels according to their own conditions and conduct treatment under the guidance of a doctor.

Reference link:https://www.tibsovo.com/